Pazopanib-induced mixed liver injury in a patient with soft-tissue sarcoma, but without theUGT1A1*28 mutation: a case report

被引：3

作者：

Hayashi, Manabu ^{[1
]}

Abe, Kazumichi ^{[1
]}

Fujita, Masashi ^{[1
]}

Takahashi, Atsushi ^{[1
]}

Kobayashi, Yasuyuki ^{[2
]}

Hashimoto, Yuko ^{[2
]}

Ohira, Hiromasa ^{[1
]}

机构：

[1] Fukushima Med Univ, Sch Med, Dept Gastroenterol, 1 Hikarigaoka, Fukushima, Fukushima 9601295, Japan

[2] Fukushima Med Univ, Sch Med, Dept Diagnost Pathol, Fukushima, Japan

来源：

CLINICAL JOURNAL OF GASTROENTEROLOGY | 2021年 / 14卷 / 01期

关键词：

Pazopanib; Liver injury; Jaundice; Steroid; RENAL-CELL CARCINOMA;

D O I：

10.1007/s12328-020-01253-x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

A 72-year-old man who underwent pazopanib therapy for soft-tissue sarcoma in the left leg was referred to our department because of elevated levels of liver enzymes. Laboratory tests showed high alanine aminotransferase, alkaline phosphatase, and total bilirubin levels. He was treated with intravenous methylprednisolone (mPSL) therapy (125 mg/day) followed by oral prednisolone and ursodeoxycholic acid therapy, but his liver enzyme abnormality deteriorated and he presented with jaundice. The intravenous mPSL (250 mg/day) treatment was effective and the abnormal levels of liver enzymes and jaundice were improved. He does not carry theUGT1A1*28 mutant allele. Based on our findings, patients presenting with markedly increased liver enzyme levels and jaundice after pazopanib may require steroid therapy.

引用

页码：224 / 228

页数：5

共 11 条

[1] EASL Clinical Practice Guidelines: Drug-induced liver injury [J].

Andrade, Raul J. ;

Aithal, Guruprasad P. ;

Bjornsson, Einar S. ;

Kaplowitz, Neil ;

Kullak-Ublick, Gerd A. ;

Karlsen, Tom H. .

JOURNAL OF HEPATOLOGY, 2019, 70 (06) :1222-1261

[2] RUCAM in Drug and Herb Induced Liver Injury: The Update [J].

Danan, Gaby ;

Teschke, Rolf .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (01)

[3] Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes [J].

Henriksen, Jakob N. ;

Bottger, Pernille ;

Hermansen, Carina K. ;

Ladefoged, Soren A. ;

Nissen, Peter H. ;

Hamilton-Dutoit, Stephen ;

Fink, Thomas L. ;

Donskov, Frede .

CLINICAL GENITOURINARY CANCER, 2020, 18 (01) :62-+

[4] POST-HALOTHANE JAUNDICE IN RELATION TO PREVIOUS ADMINISTRATION OF HALOTHANE [J].

MUSHIN, WW ;

ROSEN, M ;

JONES, EV .

BRITISH MEDICAL JOURNAL, 1971, 3 (5765) :18-&

[5] Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients [J].

Powles, Thomas ;

Bracarda, Sergio ;

Chen, Mei ;

Norry, Elliot ;

Compton, Natalie ;

Heise, Mark ;

Hutson, Thomas ;

Harter, Philipp ;

Carpenter, Christopher ;

Pandite, Lini ;

Kaplowitz, Neil .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) :1293-1302

[6] Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network [J].

Shantakumar, Sumitra ;

Nordstrom, Beth L. ;

Djousse, Luc ;

Hall, Susan A. ;

Gagnon, David R. ;

Fraeman, Kathy H. ;

van Herk-Sukel, Myrthe ;

Chagin, Karen ;

Nelson, Jeanenne .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) :559-566

[7] Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial [J].

Sternberg, Cora N. ;

Davis, Ian D. ;

Mardiak, Jozef ;

Szczylik, Cezary ;

Lee, Eunsik ;

Wagstaff, John ;

Barrios, Carlos H. ;

Salman, Pamela ;

Gladkov, Oleg A. ;

Kavina, Alexander ;

Zarba, Juan J. ;

Chen, Mei ;

McCann, Lauren ;

Pandite, Lini ;

Roychowdhury, Debasish F. ;

Hawkins, Robert E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :1061-1068

[8] A proposal of the diagnostic scale of drug-induced liver injury [J].

Takikawa, H ;

Onji, M .

HEPATOLOGY RESEARCH, 2005, 32 (04) :250-251

[9] Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study [J].

Toulmonde, Maud ;

Pulido, Marina ;

Ray-Coquard, Isabelle ;

Andre, Thierry ;

Isambert, Nicolas ;

Chevreau, Christine ;

Penel, Nicolas ;

Bompas, Emmanuelle ;

Saada, Esma ;

Bertucci, Francois ;

Lebbe, Celeste ;

Le Cesne, Axel ;

Soulie, Patrick ;

Piperno-Neumann, Sophie ;

Sweet, Stephen ;

Cecchi, Fabiola ;

Hembrough, Todd ;

Bellera, Carine ;

Kind, Michele ;

Crombe, Amandine ;

Lucchesi, Carlo ;

Le Loarer, Francois ;

Blay, Jean-Yves ;

Italiano, Antoine .

LANCET ONCOLOGY, 2019, 20 (09) :1263-1272

[10] Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial [J].

van der Graaf, Winette T. A. ;

Blay, Jean-Yves ;

Chawla, Sant P. ;

Kim, Dong-Wan ;

Binh Bui-Nguyen ;

Casali, Paolo G. ;

Schoffski, Patrick ;

Aglietta, Massimo ;

Staddon, Arthur P. ;

Beppu, Yasuo ;

Le Cesne, Axel ;

Gelderblom, Hans ;

Judson, Ian R. ;

Araki, Nobuhito ;

Ouali, Monia ;

Marreaud, Sandrine ;

Hodge, Rachel ;

Dewji, Mohammed R. ;

Coens, Corneel ;

Demetri, George D. ;

Fletcher, Christopher D. ;

Tos, Angelo Paolo Dei ;

Hohenberger, Peter .

LANCET, 2012, 379 (9829) :1879-1886

← 1 2 →